Ablative Preoperative Single-Fraction Radiation Dose Escalation Among Patients With Breast Cancer
JAMA Network Open · 2025
DOI: 10.1001/jamanetworkopen.2025.43689 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift JAMA Network Open, 2025. Verfasst von Asal Rahimi und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Texas Southwestern Medical Center, Dallas. Hauptthemen laut MEDLINE: Breast Neoplasms, Radiosurgery, Preoperative Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Single-fraction preoperative ablative stereotactic partial breast irradiation (sPBI) can be safely delivered in early-stage hormone receptor–positive (HR + ) breast cancer with delayed time to surgery and high pathologic complete response rates.
Objectives
To examine the maximum tolerated dose (MTD) of sPBI and to evaluate clinical outcomes, including pathological complete response (pCR), time to surgery, and toxic effects, associated with dose escalation. Design, Setting, and Participants This phase 1 nonrandomized clinical trial of dose escalation enrolled patients with HR + , ERBB2 -negative, cN0 invasive breast cancer not requiring chemotherapy from a single academic center between December 2019 and April 2024.
Interventions
Patients were treated with 30, 34, or 38 Gy using MR-guided linear accelerator (MR-LINAC), robotic radiosurgery, or cobalt stereotactic unit. Patients received endocrine therapy and delayed surgery (≤12 months). Main Outcomes and Measures The MTD was evaluated using dose-limiting toxicity (DLT), defined as grade 3 or higher toxic effects within 90 days. Additionally, pCR, near pCR (npCR), the association of dose escalation with time to surgery, local control, surgical morbidity, and cosmesis were evaluated.
Results
A total of 44 patients (median [range] age, 64.5 [44.0-77.0] years) were treated, with 14 (31.8%) receiving 30 Gy (median [IQR] follow-up, 52.0 [28.2-54.5] months), 15 (34.1%) receiving 34 Gy (median [IQR] follow-up, 40.0 [36.5-41.0] months), and 15 (31.4%) receiving 38 Gy (median [IQR] follow-up, 20.0 [17.0-22.0] months). MTD was not reached. pCR rates were 35.7% (5 patients), 46.7% (7 patients), and 66.7% (10 patients), while pCR with npCR rates were 64.3% (9 patients), 93.3% (14 patients), and 93.3% (14 patients), respectively. Local control was 100%, and surgical morbidity was 2.2% (1 of 44 patients). The mean (SD) Ki-67 was 11.3% (6.4%) at diagnosis, and on evaluable residual disease, it was 1.9% (2.0%) ( P < .001). A time-to-surgery threshold of 277 days was the optimal cutoff for pCR (area under the receiver operating characteristic curve, 0.77; 95% CI, 0.62-0.91). In patients with surgery more than 9 months after sPBI, pCR rates were 100% (5 of 5 patients), 66.7% (4 of 6 patients), and 64.3% (9 of 14 patients) ( P = .40), and combined pCR and npCR rates were 100%, 83.3% (5 patients), and 92.9% (13 patients) ( P = .69) for the 30, 34, and 38 Gy groups, respectively. For all patients who received surgery more than 9 months after sPBI, the pCR rate was 72.0% (18 of 25 patients). Longer time to surgery was associated with pCR (odds ratio, 1.02; 95% CI, 1.01-1.03; P = .005), while higher radiation dose was not. Acute toxic effects included 32 grade 1, 3 grade 2 (breast pain and dermatitis), and 1 late grade 3 (wound dehiscence in patient with uncontrolled diabetes) events. Cosmesis remained stable at 36 months. Conclusions and Relevance In this nonrandomized clinical trial, the rate of toxic effects was low, and treatments were tolerable up to 38 Gy. Delaying surgery more than 9 months after sPBI with endocrine therapy was associated with increased pCR and npCR (>90%), while higher doses were not. These findings support further investigation of sPBI as a potential nonsurgical approach for selected patients with early-stage HR + breast cancers. Trial Registration ClinicalTrials.gov Identifier: NCT04040569
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, University Texas Southwestern Medical Center, Dallas.
- Department of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas.
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas.
- Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas.
- Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
- Department of Medical Oncology, University of Texas Southwestern Medical Center, Dallas.
Zitieren
APA
Rahimi, A., Leitch, M., Dogan, B., Liu, Y., Alluri, P., Arbab, M., Li, X., Parsons, D. D. M., Kim, D. W. N., Wandrey, N., Farr, D., Seiler, S., Unni, N., Nguyen, A., Wooldridge, R., Chiu, T. D., Lu, W., Stojadinovic, S., Visak, J., …, & Timmerman, R. (2025). Ablative Preoperative Single-Fraction Radiation Dose Escalation Among Patients With Breast Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.43689
Vancouver
Rahimi A, Leitch M, Dogan B, Liu Y, Alluri P, Arbab M, et al. Ablative Preoperative Single-Fraction Radiation Dose Escalation Among Patients With Breast Cancer. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.43689
BibTeX
@article{Rahimi2025,
author = {Rahimi, Asal and Leitch, Marilyn and Dogan, Basak and Liu, Yulun and Alluri, Prasanna and Arbab, Mona and Li, Xingzhe and Parsons, David D M and Kim, Dong Wook Nathan and Wandrey, Narine and Farr, Deborah and Seiler, Stephen and Unni, Nisha and Nguyen, Anvy and Wooldridge, Rachel and Chiu, Tsuicheng D and Lu, Weiguo and Stojadinovic, Strahinja and Visak, Justin and Nwachukwu, Chika and Patel, Ina and Morgan, Howard and Bahrami, Shohreh and Stein, Maggie and McArthur, Heather L and Sahoo, Sunati and Timmerman, Robert},
title = {Ablative Preoperative Single-Fraction Radiation Dose Escalation Among Patients With Breast Cancer},
journal = {JAMA Network Open},
year = {2025},
doi = {10.1001/jamanetworkopen.2025.43689}
}
EUVIMED